Prestige Consumer Healthcare Inc.

What they do

The company develops, manufactures, markets, and distributes well-recognized OTC health and personal care products across mass merchandisers, drug, food, dollar, convenience, club stores, and e-commerce in North America, Australia, and select international markets. It operates in two segments—North American OTC Healthcare and International OTC Healthcare—and grows both organically and through acquisitions of established brands.

Revenue drivers

• North American OTC Healthcare — Core segment, producing 83.9% of fiscal 2026 revenue; includes major brands such as BC/Goody's analgesics, Chloraseptic, Clear Eyes, DenTek, and Dramamine.
• International OTC Healthcare — 16.1% of fiscal 2026 revenue, with growth driven by acquired brands like Breathe Right and existing international product sales.
• Major Brands Portfolio — About 83.5% of fiscal 2026 total revenue comes from major brands, which hold #1 or top market positions in categories like analgesic powders, sore throat liquids, wart removal, ear wax removal, and motion sickness.

Recent performance

In fiscal Q1 2027 (ended June 30, 2026), revenue was $265.7 million, up 6.5% year-over-year, with organic growth of 3.2% (excluding FX and a $5.9 million Breathe Right contribution). Reported diluted EPS fell to $0.61 from $0.95 due to acquisition-related costs, but adjusted diluted EPS rose to $0.98 from $0.95. Net cash from operations was $70.8 million versus $79.0 million in the prior year period. Fiscal 2026 full-year revenue was $1.09 billion with net income of $190.3 million and diluted EPS of $3.91.

Strategy

Prestige continues to acquire and integrate well-known OTC brands, as seen in the June 2026 $1.045 billion acquisition of Breathe Right and related brands and the December 2025 acquisition of Pillar5, a Clear Eyes supplier turned in-house ophthalmic manufacturer. The company invests in advertising, brand extensions, and innovative product development to drive market share and distribution. Management also focuses on organic growth, capital allocation, and cost efficiencies, while using acquisitions to strengthen production capabilities. The company is expanding internationally, leveraging acquired brands to fuel segment growth.

Risks

• Supply chain and manufacturing dependence — The company relies on third-party manufacturers for many products; disruptions could impact production and sales.
• Customer concentration and retail inventory changes — A large portion of revenue comes from a limited number of mass-market and drug retailers, who can adjust inventory and promotional demands.
• Regulatory and trade policy changes — Manufacturing plants, advertising, and products are subject to regulatory actions, and tariffs or trade restrictions could raise costs or limit international sales.
• High leverage and acquisition integration — The Breathe Right purchase added $1.045 billion in term loans, boosting debt to about $2.0 billion; integration issues or slower-than-expected deleveraging could strain the balance sheet.

Outlook

Management raised fiscal 2027 guidance to include the Breathe Right and LaCorium acquisitions, expecting revenue of $1.290 to $1.315 billion and adjusted diluted EPS of $4.55 to $4.65. They cite strong consumption for leading brands and plan to rapidly deleverage after closing acquisitions, while anticipating continued economic volatility and consumer shifts to online purchasing.